Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PharmaCyte Biotech (PMCB)
NASDAQ:PMCB
Holding PMCB?
Track your performance easily
PMCB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.39 - $2.58
Previous Close$1.7
Volume6.91K
Average Volume (3M)35.34K
Market Cap
$13.05M
Enterprise Value-$19.58M
Total Cash (Recent Filing)$32.64M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)2.5
Beta0.84
Next Earnings
Mar 16, 2022EPS Estimate
-$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.67
Shares Outstanding7,679,045
10 Day Avg. Volume17,619
30 Day Avg. Volume35,337
Standard Deviation0.31
R-Squared0.00117
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.28
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda-0.76
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Ownership Overview
―
Insiders
4.59% Mutual Funds
3.81% Other Institutional Investors
88.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PMCB FAQ
What was PharmaCyte Biotech’s price range in the past 12 months?
PharmaCyte Biotech lowest stock price was $1.39 and its highest was $2.58 in the past 12 months.
What is PharmaCyte Biotech’s market cap?
Currently, no data Available
When is PharmaCyte Biotech’s upcoming earnings report date?
PharmaCyte Biotech’s upcoming earnings report date is Mar 16, 2022 which is 986 days ago.
How were PharmaCyte Biotech’s earnings last quarter?
PharmaCyte Biotech released its earnings results on Dec 15, 2021. The company reported -$0.06 earnings per share for the quarter, the consensus estimate of -$0.06 by $0.
Is PharmaCyte Biotech overvalued?
According to Wall Street analysts PharmaCyte Biotech’s price is currently Overvalued.
Does PharmaCyte Biotech pay dividends?
PharmaCyte Biotech does not currently pay dividends.
What is PharmaCyte Biotech’s EPS estimate?
PharmaCyte Biotech’s EPS estimate is -$0.05.
How many shares outstanding does PharmaCyte Biotech have?
PharmaCyte Biotech has 7,679,045 shares outstanding.
What happened to PharmaCyte Biotech’s price movement after its last earnings report?
PharmaCyte Biotech reported an EPS of -$0.06 in its last earnings report, expectations of -$0.06. Following the earnings report the stock price went down -0.481%.
Which hedge fund is a major shareholder of PharmaCyte Biotech?
Among the largest hedge funds holding PharmaCyte Biotech’s share is Carolina Wealth Advisors, LLC. It holds PharmaCyte Biotech’s shares valued at 3.
---
PharmaCyte Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.07%
12-Months-Change
Fundamentals
Return on Equity
47.88%
Trailing 12-Months
Asset Growth
-12.13%
Trailing 12-Months
Company Description
PharmaCyte Biotech
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.
---
Technical Analysis
---